Instrument Inactif

Communiqués Five Prime Therapeutics, Inc.

Actions

FPRX

US33830X1046

Recherche biotechnologique et médicale

Communiqués

16/04/21	FIVE PRIME THERAPEUTICS, INC. : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	AQ
16/04/21	Amgen : Successfully Completes Acquisition Of Five Prime Therapeutics	PR
15/04/21	FIVE PRIME THERAPEUTICS, INC. : Other Events (form 8-K)	AQ
22/03/21	Five Prime Therapeutics : Annual Report (SEC Filing - 10-K)	PU
22/03/21	FIVE PRIME THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	AQ
12/03/21	FIVE PRIME INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Five Prime Therapeutics - FPRX	BU
09/03/21	Five Prime Therapeutics : Cancels Fourth Quarter and Full-Year 2020 Financial Results Conference Call	BU
04/03/21	FIVE PRIME THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
04/03/21	Amgen : To Acquire Five Prime Therapeutics For $1.9 Billion in Cash	PR
02/03/21	Five Prime Therapeutics : Announces Timing of Its Fourth Quarter 2020 and Full Year Results Conference Call	BU
26/02/21	Five Prime Therapeutics : to Participate in the Cowen 41st Annual Health Care Conference	BU
25/02/21	Five Prime Therapeutics : Corporate Overview February 2020	PU
23/02/21	Five Prime Therapeutics : to Participate in the SVB Leerink 10th Annual Global Healthcare Conference	BU
05/02/21	Five Prime Therapeutics to Participate in Guggenheim Healthcare Talks 2021: Oncology Day	BU
15/01/21	FIVE PRIME THERAPEUTICS, INC. : Results of Operations and Financial Condition (form 8-K)	AQ
15/01/21	Five Prime Therapeutics : Bema P2 Data Presentation KOL Event	PU
15/01/21	FIVE PRIME THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)	AQ
15/01/21	Five Prime Therapeutics : Phase 2 FIGHT Trial Results Presented at ASCO GI Validate Importance of FGFR2b Overexpression and Reinforce Potential of Bemarituzumab Plus Chemotherapy as a Frontline Targeted Treatment for FGFR2b+ Gastric and GEJ Cancers	BU
09/12/20	Five Prime Therapeutics : to Present Phase 2 FIGHT Trial Results of Bemarituzumab at American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Virtual Annual Symposium	BU
17/11/20	FIVE PRIME THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)	AQ
17/11/20	Five Prime Therapeutics : Announces Closing of Upsized Public Offering of Common Stock	BU
13/11/20	FIVE PRIME THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
13/11/20	Five Prime Therapeutics : Announces Pricing of Upsized Public Offering of Common Stock	BU
11/11/20	Five Prime Therapeutics : Presents First Preclinical Data on Anti-CCR8 Antibody FPA157	BU
11/11/20	Five Prime Therapeutics : Announces Proposed Public Offering of Common Stock	BU